Laserfiche WebLink
<br />C-7 <br /> <br /> <br />6. Janssen shall not compensate or support Health Care Providers or organizations to <br />advocate for formulary access or treatment guideline changes for the purpose of <br />increasing access to any Opioid Product through third-party payors, i.e., any entity, <br />other than an individual, that pays or reimburses for the dispensing of prescription <br />medicines, including but not limited to managed care organizations and pharmacy <br />benefit managers. <br />7. No officer or management-level employee of Janssen may concurrently serve as a <br />director, board member, employee, agent, or officer of any entity that primarily <br />engages in conduct that Promotes Opioids, Opioid Products, or products for the <br />treatment of Opioid-induced side effects. For the avoidance of doubt, nothing in this <br />provision shall preclude an officer or management-level employee of Janssen from <br />concurrently serving on the board of a hospital. <br />8. Janssen shall play no role in appointing persons to the board, or hiring persons to the <br />staff, of any entity that primarily engages in conduct that Promotes Opioids, Opioid <br />Products, or products for the treatment of Opioid-induced side effects. For avoidance <br />of doubt, nothing in this paragraph shall prohibit Janssen from fully and accurately <br />responding to unsolicited requests or inquiries about a person’s fitness to serve as an <br />employee or Board member at any such entity. <br />F. Lobbying Restrictions <br />1. Janssen shall not Lobby for the enactment of any federal, state, or local legislative or <br />regulatory provision that: <br />a. Encourages or requires Health Care Providers to prescribe Opioids or <br />sanctions Health Care Providers for failing to prescribe Opioids or failing to <br />treat pain with Opioids; <br />b. Has the effect of limiting access to any non-Opioid alternative pain <br />treatments; or <br />c. Pertains to the classification of any Opioid or Opioid Product as a scheduled <br />drug under the Controlled Substances Act. <br />2. Janssen shall not Lobby against the enactment of any federal, state or local <br />legislative or regulatory provision that supports: <br />a. The use of non-pharmacologic therapy and/or non-Opioid pharmacologic <br />therapy to treat chronic pain over or instead of Opioid use, including but not <br />limited to third party payment or reimbursement for such therapies; <br />b. The use and/or prescription of immediate release Opioids instead of extended <br />release Opioids when Opioid use is initiated, including but not limited to <br />third party reimbursement or payment for such prescriptions;